{"id":"atropine-ophthalmic-0-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Photophobia"},{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Systemic anticholinergic effects (rare with topical use)"}]},"_chembl":{"chemblId":"CHEMBL4557433","moleculeType":"Unknown","molecularWeight":"289.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atropine is an anticholinergic agent that competitively antagonizes muscarinic receptors on the iris sphincter muscle and ciliary muscle. This prevents parasympathetic-mediated pupil constriction and accommodation, resulting in mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation). In the context of myopia control, atropine may work by reducing accommodation-induced axial elongation of the eye.","oneSentence":"Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:57.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myopia control in children (Phase 3)"},{"name":"Cycloplegia for refraction"},{"name":"Pupil dilation for ophthalmic examination"}]},"trialDetails":[{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT07033442","phase":"NA","title":"Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery","status":"COMPLETED","sponsor":"Ataturk Training and Research Hospital","startDate":"2015-07-23","conditions":"Anaesthesia, Intraocular Pressure, Trendelenburg Position","enrollment":60},{"nctId":"NCT05667454","phase":"PHASE3","title":"MAD Trial: Myopia Atropine Dose","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2022-12-19","conditions":"Progressive Myopia","enrollment":550},{"nctId":"NCT00748059","phase":"PHASE1","title":"The Pathophysiology of Orthostatic Hypotension","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"1996-12","conditions":"Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency","enrollment":10},{"nctId":"NCT01844258","phase":"NA","title":"Modified Surgical Techniques for Pediatric Cataract Treatment","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2013-03","conditions":"Cataract","enrollment":37},{"nctId":"NCT00371124","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children","status":"UNKNOWN","sponsor":"Singapore National Eye Centre","startDate":"2006-03","conditions":"Myopia","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Atropine Ophthalmic 0.5%","genericName":"Atropine Ophthalmic 0.5%","companyName":"Erasmus Medical Center","companyId":"erasmus-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation. Used for Myopia control in children (Phase 3), Cycloplegia for refraction, Pupil dilation for ophthalmic examination.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}